Literature DB >> 1565113

Cyclosporin A therapy in paraprotein-associated neuropathy.

J A Waterston1, M M Brown, D A Ingram, M Swash.   

Abstract

A case of IgG paraprotein-associated demyelinating neuropathy complicated by respiratory failure, which was unresponsive to standard immunosuppressive drug therapy, is reported. Cyclosporin A therapy resulted in a marked clinical recovery with objective improvement in nerve conduction and vital capacity. The beneficial response suggests that cell-mediated immunity is an important pathogenetic mechanism, and that cyclosporin A may be useful in the treatment of other refractory cases of paraprotein-associated neuropathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565113     DOI: 10.1002/mus.880150404

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.

Authors:  W Mahattanakul; T O Crawford; J W Griffin; J M Goldstein; D R Cornblath
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

3.  Soluble interleukin-2 receptor levels in serum of patients with demyelinating polyneuropathy associated with monoclonal gammopathy.

Authors:  A J Larner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.